Company Profile

Kalgen Inc
Profile last edited on: 1/5/07      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
----
First Award
1995
Latest Award
1999
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7400 Louis Pasteur Suite 105B
San Antonio, TX 78229
   (210) 567-3825
   klebe@uthscsa.edu
   N/A
Location: Single
Congr. District: 20
County: Bexar

Public Profile

Our laboratory is interested in the control of morphogenesis by homeobox genes. The homeobox genes provide the highest level of control during embryonic development. While the molecular genetics of the homeobox genesis now well established, the genes controlled by the homeobox genes is currently unknown. We are currently testing a new theory, proposed by Gerald Edelman, that postulates that the homeobox genes primarily regulate the expression of cell adhesion proteins and their receptors. We are also interested in a new area, termed tissue engineering. Tissue engineering involves creating tissues and organs from single cells. We have developed a computerized technique that permits one to microposition cells within a cell diameter on any substratum

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1999 2 NIH $629,426
Project Title: Selecting New Coding Sequences by PCR with CDNA Primers
1998 1 NIH $99,999
Project Title: Tissue Engineering of Oral Tissues

Key People / Management

  Robert J Klebers -- President

  Pudur Jagadeeswaran

Company News

There are no news available.